Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KIF5B | P33176 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30238805 | 0.97 | EHMT2 (0.47) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL29565656 | 0.97 | EHMT2 (0.47) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL30239317 | 0.97 | EHMT2 (0.47) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL30239434 | 0.94 | EHMT2 (0.45) | EHMT2DNMT1HRH3EHMT1KDM4E | |
| SCHEMBL29566469 | 0.91 | EHMT2 (0.44) | EHMT2DNMT1HRH3EHMT1KDM4E | |
| SCHEMBL30238871 | 0.87 | EHMT2 (0.45) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL30238747 | 0.87 | EHMT2 (0.45) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL30239028 | 0.87 | EHMT2 (0.45) | EHMT2DNMT1HRH3EHMT1RET | |
| SCHEMBL19260698 | 0.86 | EHMT2 (0.46) | EHMT2DNMT1EHMT1 | |
| SCHEMBL29565929 | 0.85 | TSHR (0.44) | EHMT2DNMT1EHMT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885DNMT1 24/4885HRH3 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.